Introduction
============

The global emergence of multidrug-resistant (MDR) Gram-negative bacteria is a growing threat to public health worldwide ([@B16]). Due to the diversity of resistance mechanisms that may lead to MDR or even pandrug resistance (PDR; [@B18]; [@B25]), *Acinetobacter baumannii* and *Pseudomonas aeruginosa* are among the increasingly reported and commonly identified MDR or even PDR nosocomial pathogens. They are responsible for many hospital-acquired infections, ranging from mild skin wounds and urinary tract infections to severe life-threatening infections, including bloodstream, pneumonia, and meningitis ([@B12]; [@B1]). At the same time, the progress in developing new antibiotics against these pathogens is slow ([@B10]). Therefore, new strategies for controlling these MDR pathogens are urgently needed.

Bacteriophage lysins, the weapon of phages to digest the host bacterial cell wall for the release of progeny phages, have been extensively demonstrated to be promising alternatives in the treatment of Gram-positive pathogens, such as staphylococci and streptococci ([@B22]; [@B24]; [@B29]). Due to their unique working mechanisms, lysins possess a low possibility of developing resistance ([@B11]; [@B14]). However, the outer membranes of Gram-negative bacteria block the access of natural lysins to their peptidoglycan substrates, thus making the exogenously added lysins useless or very weak against the viability of the target cells ([@B21]; [@B15]; [@B17]).

Currently, several strategies have been developed to break the barriers posed by the outer membranes of Gram-negative bacteria to natural lysins. Physical (i.e., high hydrostatic pressure; [@B2]) and chemical permeabilizers (i.e., EDTA, and weak organic acid, usually citric acid; [@B4], [@B7]) can permeabilize the outer membrane efficiently to enhance the antibacterial activity of lysins, but are only applicable in applications such as food conservation and the treatment of topical infections. Structure-based engineering and phage genome-based screening methods have also been used to find novel lysins that act on *Yersinia* with the FyuA receptor ([@B20]) and *A. baumannii* ([@B19]). In recent years, a few engineered lysins have been reported with good antibacterial activities against *P. aeruginosa* by fusing natural lysins with optimized N- or C-terminal lipopolysaccharides-destabilizing or antimicrobial peptides, respectively, which can permeabilize the outer membranes ([@B5],[@B6]). In principle, considering the easy availability of lipopolysaccharide-destabilizing and antimicrobial peptides, fusing natural lysins with such peptides looks quite attractive since it provides a good way with plenty of chances to create novel engineered lysins against Gram-negative bacteria. However, reports on peptide-modified lysins are limited, and mainly focus on *P. aeruginosa*.

In the present study, a new peptide-modified lysin (PlyA) against *A. baumannii* and *P. aeruginosa* was constructed by fusing the cecropin A peptide residues 1--8 (KWKLFKKI) with the OBPgp279 lysin ([@B27]), and its antibacterial activity was evaluated.

Materials and Methods {#s1}
=====================

Bacterial Strains
-----------------

All bacterial strains and clinical isolates (**Table [1](#T1){ref-type="table"}**) used in this work were grown in Luria Broth (LB) medium at 37°C. All clinical isolates of *A. baumannii* and *P. aeruginosa* were identified by 16S rDNA sequencing analysis combined with the biochemistry test using a MicroStation system (Biolog, GEN III Omnilog Combo Plus System, USA).

###### 

Bacterial strains and clinical isolates used in this work.

  Strain                             Antibiogram                  Strain                            Antibiogram
  ---------------------------------- ---------------------------- --------------------------------- ----------------------------
  ***Acinetobacter baumannii*^a^**                                ***Pseudomonas aeruginosa*^a^**   
  WHG3047                            ND                           WHG3012                           Ak^S^, Ge^S^, Cf^S^, Im^S^
  WHG3051                            ND                           WHG3022                           Ak^S^, Ge^R^, Cf^R^, Im^R^
  WHG3059                            ND                           WHG3029                           Ak^S^, Ge^S^, Cf^S^, Im^S^
  WHG3072                            Ak^R^, Ge^R^, Cf^R^, Im^R^   WHG3014                           Ak^S^, Ge^S^, Cf^S^, Im^S^
  WHG3074                            Ak^R^, Ge^R^, Cf^R^, Im^R^   WHG3015                           Ak^S^, Ge^S^, Cf^R^, Im^S^
  WHG3075                            Ak^R^, Cf^R^, Im^R^          WHG3028                           Ak^S^, Ge^S^, Cf^R^, Im^R^
  WHG3032                            Ak^S^, Ge^S^, Cf^S^, Im^S^   WHG3030                           Ak^S^, Cf^S^, Im^S^
  WHG3064                            Ak^S^, Ge^S^, Cf^S^, Im^S^   WHG3013                           Ak^R^, Ge^R^, Cf^R^, Im^R^
  WHG3078                            Ak^R^, Ge^R^, Cf^R^, Im^R^   WHG3043                           Ak^S^, Ge^S^, Cf^S^, Im^R^
  WHG3048                            ND                           WHG3006                           Ak^S^, Ge^S^, Cf^S^, Im^S^
  WHG3049                            ND                           WHG3007                           Ak^S^, Ge^S^, Cf^S^, Im^R^
  WHG3050                            ND                           WHG3008                           Ak^S^, Ge^S^, Cf^S^, Im^R^
  WHG3052                            ND                           WHG3009                           Ak^S^, Ge^S^, Cf^S^, Im^R^
  WHG3053                            ND                           WHG3016                           Ak^S^, Ge^S^, Cf^S^, Im^I^
  WHG3054                            ND                           WHG3018                           Ak^S^, Ge^S^, Cf^S^, Im^S^
  WHG3082                            Ak^S^, Ge^S^, Cf^S^, Im^S^   WHG3021                           Ak^S^, Ge^S^, Cf^S^, Im^R^
  WHG3073                            Ak^R^, Ge^R^, Cf^R^, Im^R^   WHG3019                           Ak^S^, Ge^S^, Cf^R^, Im^R^
  WHG3070                            Ak^R^, Ge^R^, Cf^R^, Im^R^   WHG3024                           Ak^R^, Ge^R^, Cf^R^, Im^R^
  WHG3071                            Ak^R^, Ge^R^, Cf^R^, Im^R^   WHG3025                           Ak^S^, Ge^S^, Cf^S^, Im^R^
  WHG3077                            Ak^R^, Ge^R^, Cf^R^, Im^R^   WHG3026                           Ak^S^, Ge^S^, Cf^S^, Im^S^
  WHG3083                            Ak^R^, Ge^R^, Cf^R^, Im^R^   WHG3031                           Ak^R^, Ge^R^, Cf^R^, Im^R^
  WHG3079                            Ak^R^, Ge^R^, Cf^R^, Im^R^   WHG3033                           Ak^S^, Ge^S^, Cf^S^, Im^R^
  WHG3080                            Ak^R^, Ge^R^, Cf^R^, Im^R^   WHG3034                           Ak^S^, Ge^S^, Cf^S^, Im^S^
  WHG3081                            Ak^R^, Ge^R^, Cf^R^, Im^R^   WHG3036                           Ak^S^, Ge^S^, Cf^S^, Im^S^
  WHG3056                            Ak^S^, Ge^S^, Cf^S^, Im^S^   WHG3017                           Ak^S^, Ge^S^, Cf^S^, Im^S^
  WHG3058                            Ak^R^, Ge^R^, Cf^R^, Im^R^   WHG3037                           Ak^S^, Ge^S^, Cf^S^, Im^S^
  WHG3061                            Ak^R^, Ge^R^, Cf^R^, Im^R^   WHG3039                           Ak^S^, Ge^R^, Cf^S^, Im^S^
  WHG3063                            Ak^S^, Ge^R^, Cf^R^, Im^R^   WHG3038                           Ak^R^, Ge^R^, Cf^R^, Im^R^
  WHG3062                            Ak^R^, Ge^R^, Cf^R^, Im^S^   WHG3040                           Ak^S^, Ge^S^, Cf^I^, Im^S^
  WHG3065                            Ak^R^, Ge^R^, Cf^R^, Im^R^   WHG3041                           Ak^S^, Ge^S^, Cf^S^, Im^S^
  WHG3068                            Ak^S^, Ge^R^, Cf^R^, Im^R^   WHG3042                           Ak^S^, Ge^S^, Cf^S^, Im^S^
  WHG3066                            Ak^S^, Ge^S^, Cf^R^, Im^R^   WHG3023                           Ak^S^, Ge^S^, Cf^S^, Im^S^
  ***Escherichia coli^b^***                                       WHG3027                           Ak^S^, Ge^S^, Cf^R^, Im^R^
  BL21(DE3)                          ND                           WHG3029                           Ak^S^, Ge^S^, Cf^S^, Im^S^
  ***Bacillus cereus^b^***                                        WHG3014                           Ak^S^, Ge^S^, Cf^S^, Im^S^
  IS195                              ND                           WHG3015                           Ak^R^, Ge^R^, Cf^S^, Im^R^

Antibiogram: Ak, amikacin; Ge, gentamicin; Cf, cefepime; Im, imipenem; ND, not detected; R, resistant; S, susceptible; I, intermediate-resistant

.

a

Isolated from Zhongnan Hospital of Wuhan University;

b

Lab collection

.

Construction of Plasmids
------------------------

Cecropin A is a 37-residue membrane-active antimicrobial polypeptide that kills bacteria by dissipating transmembrane electrochemical ion-gradients ([@B26]). Because the N-terminal residues 1--8 of cecropin A (CA, KWKLFKKI) are highly positively charged, this fragment was used in this study. OBPgp279 coding sequence was initially cloned into the modified pET28a(+) plasmid (Kan^R^) containing a (G4S)~2~ liner between *Bam*HI and *Eco*RI sites ([@B28]), using primers OBP-F (5-tatagaattcatgaaaaactcggaaaagaacg-3) and OBP-R (5-atatctcgagcacgatacccagagcttttttg-3), to obtain pET-*OBPgp279* vector (Kan^R^). The coding sequence for cecropin A peptide residues 1--8 (CA, KWKLFKKI) was cloned into the pET-*OBPgp279* vector, using primers CA-F (5-catgggcaaatggaaattatttaagaaaattg-3) and CA-R (5-gatccaattttcttaaataatttccatttgcc-3), to obtain pET-CA-*OBPgp279* (pET-PlyA, Kan^R^) vector. After verification by sequencing, *E. coli* BL21(DE3) cells were transformed with the correct plasmid for protein expression.

Protein Purification
--------------------

The recombinant enzymes were purified as described previously in our laboratory ([@B13]). Briefly, the *E. coli* BL21(DE3) cells were induced with 0.5 mM isopropyl β-[D]{.smallcaps}-thiogalactoside (IPTG) overnight at 16°C and collected for protein purification after sonication on ice. Then the proteins were collected by washing and eluting with 80 and 400 mM imidazole through a nickel nitrilotriacetic acid column (GE Healthcare, US), respectively. The collected active protein fractions were pooled and dialyzed against 20 mM Tris-HCl (pH 7.4) and stored at --80°C until use (less than 2 weeks).

Antibacterial Activity Assay
----------------------------

To determine the antibacterial activity of PlyA, logarithmic (cultured for 3--4 h, OD~600~ = 0.6--0.8) or stationary phase (cultured for 14--16 h, OD~600~ = 1.4--1.6) cultures of *A. baumannii* WHG3066 were centrifuged (10,000 *g* × 1 min) first. Then the cells were washed once and resuspended in 20 mM Tris-HCl (pH 7.4). Bacterial suspensions (100 μl) were mixed with the enzyme in the presence or absence of the outer membrane permeabilizers (OMPs, i.e., EDTA and citric acid) at 37°C for 15--60 min. Finally, the remaining viable cells were calculated by plating onto LA plates. For susceptibility test, clinical isolates of *A. baumannii* and *P. aeruginosa* were cultured to logarithmic phase and treated with 50 (for *A. baumannii* isolates) or 100 μg/ml (for *P. aeruginosa* isolates) PlyA at 37°C for 1 h. All assays were performed for at least three times in biological repeats.

To test the synergism between OMPs and PlyA, stationary phase *A. baumannii* WHG3066 and *P. aeruginosa* WHG3012 cells were treated with 100 μg/ml PlyA in the presence of various concentrations of EDTA or citric acid in 20 mM Tris-HCl (pH 7.4) or 5 mM HEPES-NaOH (pH 7.4) at 37°C for 1 h. Afterward, the viable cell numbers were counted by plating. To avoid the acidification effect of citric acid, the synergism between citric acid and PlyA was also performed by adjusting the pH values of the reaction systems to 7.4. All assays were performed for at least three times in biological repeats.

To test the effects of bio-matrix on the antibacterial activity of PlyA, *A. baumannii* WHG3066 cells in logarithmic phase were washed once with 20 mM Tris-HCl buffer (pH 7.4), and resuspended in medium, including LB, Mueller--Hinton (MH, Huankai Microbial, Guangdong, China), Brain Heart Infusion (BHI, Huankai Microbial, Guangdong, China) and Tryptic Soy Broth (TSB, Becton, Dickinson & Co., France) with 4% NaCl (TSBN), or pasteurized milk (Mengniu Group, Wuhan, China), or human serum (Sigma--Aldrich, Shanghai, China). Then, cells were treated with 100 μg/ml PlyA at 37°C for 1 h, respectively. The viable cell numbers were evaluated by plating on LA plates. All assays were performed for at least three times in biological repeats.

Transmission Electron Microscope (TEM)
--------------------------------------

The action of PlyA on the cell wall of the bacteria was monitored by a thin-section transmission electron microscope (Tecnai G^2^ 20 TWIN, FEI, USA). Briefly, *A. baumannii* WHG3066 cell suspensions in logarithmic phase were incubated with 100 μg/ml PlyA at 37°C for 10, 15, and 30 min, respectively. Then, the reactions were terminated by addition of 2.5% glutaraldehyde and the fixed samples were analyzed by transmission electron microscope (TEM). Cells treated with 20 mM Tris-HCl (pH 7.4) under the same conditions were used as controls.

Results
=======

Characteristics of PlyA in Tris-HCl Buffer
------------------------------------------

As shown in **Figure [1A](#F1){ref-type="fig"}**, CA-fused OBPgp279 (called PlyA for short) and its parental lysin OBPgp279 were well expressed in *E. coli* as soluble proteins with purity of \>95% as observed by 12% SDS-PAGE gel. Antibacterial activity tests showed that PlyA could kill logarithmic phase *A. baumannii* WHG3066 and *P. aeruginosa* WHG3012 cells rapidly in a dose-dependent manner (**Figure [1B](#F1){ref-type="fig"}**). Specifically, a reduction of over 5 logs (from 6.6 log to 1.2 log) was observed after treating the *A. baumannii* cells with 50 μg/ml PlyA for 1 h (**Figure [1B](#F1){ref-type="fig"}**), and a reduction about 2.5 logs (from 6.7 log to 3.8 log at 100 μg/ml PlyA) for *P. aeruginosa* cells (**Figure [1B](#F1){ref-type="fig"}**). Nearly no viable *A. baumannii* cells were detected when the concentration of PlyA increased to 100 μg/ml. While its parental lysin OBPgp279 (with equimolar) could only cause a reduction of about 1.38 logs (data not shown). The time kill curve revealed that the viable *A. baumannii* cell numbers were reduced about 1.8 logs (from 6.6 log to 4.8 log) within the first 15 min when treated with 50 μg/ml PlyA, and the killing continued for at least 60 min (**Figure [1C](#F1){ref-type="fig"}**).

![**Activity of peptide-modified lysin (PlyA) in Tris-HCl buffer. (A)** Analysis of purified proteins on 12% SDS-PAGE gel. **(B)** Dose-dependent antibacterial activity of PlyA against logarithmic *Acinetobacter baumannii* WHG3066 and *Pseudomonas aeruginosa* WHG3012 in 20 mM Tris-HCl (pH 7.4). **(C)** Time-killing curve of 50 μg/ml PlyA against logarithmic *A. baumannii* WHG3066. **(D--G)** Transmission electron microscope (TEM) images of logarithmic *A. baumannii* WHG3066 exposed to PlyA. TEM analysis revealed that *A. baumannii* cells exposed to 100 μg/ml PlyA suffered from extrusion **(D)** and rapid disruption at single **(E)** or multiple sites **(F)**, resulting in the loss of cytoplasmic contents and ultimately the formation of ghost cell **(G)**. Bar sizes: 200 nm.](fmicb-06-01471-g001){#F1}

Transmission electron microscope Images revealed that the *A. baumannii* WHG3066 cells exposed to PlyA suffered from leakage (**Figure [1D](#F1){ref-type="fig"}**) and rapid disruption at single (**Figure [1E](#F1){ref-type="fig"}**) or multiple sites (**Figure [1F](#F1){ref-type="fig"}**), resulting in the partial or total loss of cytoplasmic contents and ultimately loss of cell integrity (**Figure [1G](#F1){ref-type="fig"}**).

Antibacterial Spectrum of PlyA
------------------------------

Next, we tested the susceptibility of a collection of clinical isolates of *A. baumannii* and *P. aeruginosa* to PlyA (in Tris-HCl), including another 31 *A. baumannii* isolates and 35 *P. aeruginosa* isolates with multiple antimicrobial resistances profiles (**Table [1](#T1){ref-type="table"}**). The plating assay revealed that PlyA was active against all *A. baumannii* isolates tested, causing a reduction of 1.0--4.2 logs. Except WHG3033, all *P. aeruginosa* isolates tested (35/36) were susceptible to PlyA (with a reduction of 0.5--2.7 logs in viable cell number; **Figure [2](#F2){ref-type="fig"}**). The variable susceptibility of these clinical isolates to PlyA may be due to their different modifications in their outer membrane structure. No antibacterial activity of PlyA was observed against *Escherichia coli* BL21(DE3) and *Bacillus cereus* IS195 tested (data not shown). These results demonstrate that PlyA has broad antibacterial activity against MDR *A. baumannii* and *P. aeruginosa* isolates in Tris-HCl buffer.

![**Antibacterial activity of PlyA against clinical isolates of *A. baumannii* and *P. aeruginosa* in 20 mM Tris-HCl (pH 7.4). (A)** Antibacterial activity of PlyA (50 μg/ml) against *A. baumannii* clinical isolates in logarithmic phase at 37°C for 1 h. **(B)** Antibacterial activity of PlyA (100 μg/ml) against *P. aeruginosa* clinical isolates in logarithmic phase at 37°C for 1 h.](fmicb-06-01471-g002){#F2}

Bacterial Phase Affects the Antibacterial Activity of PlyA
----------------------------------------------------------

Although PlyA showed good antibacterial activity (from 6.8 log to 1.8 log) against logarithmic phase *A. baumannii* (**Figure [1C](#F1){ref-type="fig"}**), only a minor activity (from 6.8 log to 6.4 log) could be observed after treatment of the stationary phase *A. baumannii* WHG3066 cells with 50 μg/ml PlyA for 1 h (**Figure [3A](#F3){ref-type="fig"}**). Different susceptibilities to PlyA were also observed for logarithmic and stationary phase *P. aeruginosa* WHG3012 cells, but the stationary cells were still killed with a reduction of approximately 2 logs in cell number (**Figure [3B](#F3){ref-type="fig"}**). These results show that stationary phase *A. baumannii* and *P. aeruginosa* cells are not or partially killed in comparison to their logarithmic phase ones, respectively.

![**Comparison between the activity of PlyA against *A. baumannii* WHG3066 **(A)** and *P. aeruginosa* WHG3012 **(B)** cells in logarithmic and stationary phase at 37°C for 1 h in 20 mM Tris-HCl (pH 7.4).** Concentration of PlyA: 50 μg/ml.](fmicb-06-01471-g003){#F3}

OMPs Enhance the Antibacterial Activity of PlyA Against Stationary Phase Cells
------------------------------------------------------------------------------

Outer membrane permeabilizers (OMPs), such as EDTA and citric acid have been used to enhance the bacteriolytic activity of lysins ([@B23]). However, an unneglectable minor killing effect on logarithmic *P. aeruginosa* was noted in the presence of EDTA ([@B27]) and citric acid alone ([@B23]) previously by other researchers. Therefore, we only tested the synergism of these OMPs with PlyA against stationary phase cells. **Figure [4A](#F4){ref-type="fig"}** showed that EDTA alone has a minor killing effect on stationary phase *A. baumannii* cells, with a reduction of only 0.3 logs in 20 mM Tris-HCl (pH 7.4). Whilst, an obvious enhanced antibacterial activity of PlyA was observed in the presence of EDTA, with a reduction of 2.3--3.2 logs in the viable cell number. The synergism between EDTA and PlyA was observed not only in 20 mM Tris-HCl (pH 7.4), but also in 5 mM HEPES-NaOH (pH 7.4) against stationary phase *P. aeruginosa* (with a reduction of 4.4 logs; **Figure [4B](#F4){ref-type="fig"}**). Because the acidification effect of citric acid was reported to kill logarithmic cells ([@B23]; [@B3]), we tested the effect of citric acid (0.05--2 mM) on PlyA antibacterial activity against the stationary phase cultures of *A. baumannii* by adjusting the pH values of the mixtures to 7.4 after adding citric acid to the Tris-HCl buffer. Results showed that a citric acid dose-dependent synergism between citric acid and PlyA was observed (**Figure [4C](#F4){ref-type="fig"}**), indicating that mechanisms other than the acidification effect exist underlying the synergism between citric acid and PlyA against the stationary phase cells.

![**Effects of EDTA and citric acid on the antibacterial activity of PlyA. (A,B)** Effects of 100 μg/ml PlyA combined with various concentrations of EDTA against stationary phase *A. baumannii* WHG3066 in 20 mM Tris-HCl (pH 7.4) **(A)**, and *P. aeruginosa* WHG3012 **(B)** cells in different buffers at 37°C for 1 h. **(C)** Effects of 100 μg/ml PlyA combined with various concentrations of citric acid against stationary phase *A. baumannii* WHG3066 in 20 mM Tris-HCl (pH 7.4) with pH adjustment.](fmicb-06-01471-g004){#F4}

Antibacterial Activity of PlyA in Bio-Matrix Conditions
-------------------------------------------------------

Finally, we evaluated the performance of PlyA in some bio-matrix conditions, including LB culture medium, pasteurized milk, and human serum, which are more complicate than the pure Tris-HCl or HEPES-NaOH buffer. **Figure [5](#F5){ref-type="fig"}** showed that no antibacterial activity was observed in the presence of PlyA in these conditions against logarithmic phase *A. baumannii* cells. The abolished activity was also observed in MH, BHI, and TSBN culture media (data not shown). These results indicate that PlyA alone is easily inactivated in complicate environments, limiting its application only to relatively simple or special conditions.

![**Activity of PlyA in some matrices.** Logarithmic phase *A. baumannii* WHG3066 cells were suspended in Tris-HCl buffer (pH 7.4), LB culture medium (pH 7.0), pasteurized milk (pH 6.8), and serum (pH 6.9), respectively. After treatment with 100 μg/ml PlyA at 37°C for 1 h, the viable cell numbers were calculated by plating on LA plates. Buffer treated groups were used as controls.](fmicb-06-01471-g005){#F5}

Discussion
==========

The global emergence of MDR bacteria is calling to find novel molecules for treating the infections caused by them. Some recent studies on peptide-modified lysins or prophage lysins with similar structural compositions have shown that they could kill Gram-negative pathogens, including *P. aeruginosa* ([@B5]) and *A. baumannii* ([@B19]). However, less is known about the conditions that influence the activities of peptide-modified lysins and their potential limitations in real applications. In the present study, we found that the activity of a new peptide-modified lysin could be affected by the bacterial growth phase and the bio-matrix, which should be taken into consideration for the development of new peptide-modified lysins.

We observed that PlyA showed good antibacterial activity in Tris-HCl buffer against logarithmic phase *A. baumannii* and *P. aeruginosa* clinical isolates (**Figure [2](#F2){ref-type="fig"}**), including these with various antibiotic resistance profiles (**Table [1](#T1){ref-type="table"}**, some of them are MDR isolates). These results demonstrate that the strategy of modifying lysins with a selected peptide is powerful to obtain novel engineered lysins against Gram-negative bacteria, including MDR isolates. The action model of a well known peptide-modified lysin, Artilysin^®^, is speculated to be: (1) the peptide fused in the N- or C-terminal of a target lysin interacts with the lipopolysaccharide of the Gram-negative bacteria, resulting in the destabilization and deformation of the outer membrane; (2) the lysin moiety transfers through the outer membrane driven by the self-promoted uptake of the peptide, and (3) thus gets access to and hydrolyze its peptidoglycan substrates, ultimately gives rise to cell lysis. This hypothesized mode of action was recently confirmed by Briers and coworkers in the time-lapse microscopy of *P. aeruginosa* cells exposed to Artilysin^®^ LoGT-008 ([@B6]). The TEM analysis of *A. baumannii* cells in this study also supports this hypothesis. As shown in **Figure [1](#F1){ref-type="fig"}**, PlyA disintegrates the cell wall of *A. baumannii*, and causes the loss of cytoplasmic contents in a single or multiple sites. This observation is quite similar with the typical phenomenon of osmotic-mediated cell lysis following the actions of phage lysins against Gram-positive bacteria reported elsewhere ([@B9]).

Although PlyA showed good antibacterial activity against cells in logarithmic phase, a nearly abolished antibacterial activity was observed against stationary phase *A. baumannii* cells (**Figure [3A](#F3){ref-type="fig"}**). In case of stationary phase *P. aeruginosa* the antibacterial activity is not abolished but greatly reduced (**Figure [3B](#F3){ref-type="fig"}**). This observation is quite consistent with a recent report showing that a higher antibacterial activity of PlyF307 lysin was noted against exponentially growing *A. baumannii* ([@B19]). The different susceptibility may be due to the different structure and composition of the cell membranes between logarithmic and stationary phase cells. The outer membrane of bacteria is mainly composed of lipopolysaccharides, phospholipids and proteins, and their contents and types are varied in different environmental conditions and growth phases ([@B8]). Additionally, there may be also difference in peptidoglycan architecture between logarithmic and stationary phase cells, such as the thickness of peptidoglycan layer, which influences their susceptibility to PlyA.

The strong synergisms between PlyA and OMPs (EDTA and citric acid in Tris-HCl and HEPES-NaOH buffer) against stationary phase cultures of *A. baumannii* (**Figures [4A,C](#F4){ref-type="fig"}**) and *P. aeruginosa* cells (**Figure [4B](#F4){ref-type="fig"}**) indicate that the outer membrane of Gram-negative bacteria is indeed a physical barrier for the bacteriolytic activity of natural lysins. By combining with OMPs, PlyA may be helpful in *ex vivo* and topical applications, such as environmental or surface disinfection, but not suitable for systemic infections due to the potential risk of anti-coagulating properties of the OMPs.

Other researchers have noted that protonated form of citric acid has both chelating effect and acidification effect on bacterial cells, and the acidification effect could damage the outer membrane of Gram-negative bacteria (such as *P. aeruginosa*) and cause a reduction in viable cell number ([@B23]; [@B3]). However, in the present study, we found that the acidification-killing effect of citric acid (2 mM) was only observed in logarithmic cultures of *A. baumannii*, but not stationary phase ones (data not shown). Moreover, an obvious synergism between citric acid and PlyA was observed against the stationary phase cultures of *A. baumannii* in a citric acid dose-dependent manner when pH values were adjusted to neutral pH (**Figure [4C](#F4){ref-type="fig"}**). These results indicate that it is the chelating effect, but not acidification effect of citric acid, which enhanced the antibacterial activity of PlyA against stationary phase cultures of *A. baumannii*.

One serious shortcoming for PlyA may be its inactivation in complicate bio-matrices, including media, milk and serum (**Figure [5](#F5){ref-type="fig"}**), which means PlyA could only be used in relatively simple or specified conditions, such as material and skin surface disinfection. One possible reason for the inactivation of PlyA may be the conjugation and passivation of negatively charged molecules present in these matrices to the positively charged peptides, which may render the peptide losing the outer membrane penetrating activity.

However, in the previous reports, the efficacies of some Artilysin^®^s have been demonstrated in *P. aeruginosa* infected *Caenorhabditis elegans* model and human keratinocytes monolayer model in the presence of EDTA ([@B6]), as well as in *in vitro* case studies of dog otitis caused by *P. aeruginosa* ([@B3]). Therefore, it seems that it is not easy and straight-forward to design an engineered peptide-modified lysin which shows robust activity under infection conditions as described for Artilysin^®^s. Some optimization like fusing different peptides with different endolysins and combining with different linkers is required to obtain an antibacterial lysin with the desired properties and a robust activity ([@B6]).

Conclusion
==========

We report here a newly engineered lysin, PlyA, with high bacteriolytic activity against *A. baumannii* and *P. aeruginosa in vitro*. This study also indicated that conditions such as bacterial growth phase and the bio-matrix can influence the antibacterial activity of PlyA, suggesting that there are still some limitations that should be taken into consideration for the development of new peptide-modified lysins, and optimization is needed to obtain an antibacterial lysin with robust antibacterial activity.
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